Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: A novel target for treatment?

Olga Genin, Gideon Rechavi, Arnon Nagler, Ofer Ben-Itzhak, Kellie Nazemi, Mark Pines

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3 fusion. It is a slow-growing lesion associated with a high incidence of pulmonary and brain metastases indicating poor survival. We demonstrated that the ASPS metastases include also stromal myofibroblasts. These cells proliferate, express smooth-muscle genes, and synthesize extracellular matrix proteins, all of which are characteristics of activated myofibroblasts. The tumor cells also exhibited stromal components such as transforming growth factor beta (TGFβ)-dependent, hypoxia-regulated cytoglobin (stellate cell activation association protein, cytg/ STAP) and prolyl 4-hydroxylase, a collagen cross-linking enzyme. The pulmonary ASPS myofibroblasts synthesize serum response factor (SRF), a repressor of Smad3-mediated TGFβ signaling essential for myofibroblast differentiation and Smad3. The phosphorylated active Smad3 was found mostly in the tumor cells. The brain tumor cells express cytg/STAP, but in contrast to the lung metastases, they also express SRF, Smad3, and phospho-Smad3. Halofuginone, an inhibitor of myofibroblasts' activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. This inhibition was associated with the inhibition of TGF(3/SRF signaling, with the inhibition of myofibroblasts' activation, and with the complete loss in TFE3 synthesis by the tumor cells. These results suggest that the myofibroblasts may serve as a novel target for treatment of ASPS metastases.

Original languageEnglish (US)
Pages (from-to)940-948
Number of pages9
JournalNeoplasia
Volume10
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Alveolar Soft Part Sarcoma
Myofibroblasts
Neoplasm Metastasis
Lung
Serum Response Factor
Brain
Transforming Growth Factor beta
Neoplasms
Prolyl Hydroxylases
Genetic Translocation
Extracellular Matrix Proteins
Renal Cell Carcinoma
Heterografts
Brain Neoplasms
Smooth Muscle
Collagen
Phosphorylation
Incidence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma : A novel target for treatment? / Genin, Olga; Rechavi, Gideon; Nagler, Arnon; Ben-Itzhak, Ofer; Nazemi, Kellie; Pines, Mark.

In: Neoplasia, Vol. 10, No. 9, 09.2008, p. 940-948.

Research output: Contribution to journalArticle

Genin, Olga ; Rechavi, Gideon ; Nagler, Arnon ; Ben-Itzhak, Ofer ; Nazemi, Kellie ; Pines, Mark. / Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma : A novel target for treatment?. In: Neoplasia. 2008 ; Vol. 10, No. 9. pp. 940-948.
@article{d7336f3da693455db477643c752363b1,
title = "Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: A novel target for treatment?",
abstract = "Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3 fusion. It is a slow-growing lesion associated with a high incidence of pulmonary and brain metastases indicating poor survival. We demonstrated that the ASPS metastases include also stromal myofibroblasts. These cells proliferate, express smooth-muscle genes, and synthesize extracellular matrix proteins, all of which are characteristics of activated myofibroblasts. The tumor cells also exhibited stromal components such as transforming growth factor beta (TGFβ)-dependent, hypoxia-regulated cytoglobin (stellate cell activation association protein, cytg/ STAP) and prolyl 4-hydroxylase, a collagen cross-linking enzyme. The pulmonary ASPS myofibroblasts synthesize serum response factor (SRF), a repressor of Smad3-mediated TGFβ signaling essential for myofibroblast differentiation and Smad3. The phosphorylated active Smad3 was found mostly in the tumor cells. The brain tumor cells express cytg/STAP, but in contrast to the lung metastases, they also express SRF, Smad3, and phospho-Smad3. Halofuginone, an inhibitor of myofibroblasts' activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. This inhibition was associated with the inhibition of TGF(3/SRF signaling, with the inhibition of myofibroblasts' activation, and with the complete loss in TFE3 synthesis by the tumor cells. These results suggest that the myofibroblasts may serve as a novel target for treatment of ASPS metastases.",
author = "Olga Genin and Gideon Rechavi and Arnon Nagler and Ofer Ben-Itzhak and Kellie Nazemi and Mark Pines",
year = "2008",
month = "9",
doi = "10.1593/neo.08456",
language = "English (US)",
volume = "10",
pages = "940--948",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma

T2 - A novel target for treatment?

AU - Genin, Olga

AU - Rechavi, Gideon

AU - Nagler, Arnon

AU - Ben-Itzhak, Ofer

AU - Nazemi, Kellie

AU - Pines, Mark

PY - 2008/9

Y1 - 2008/9

N2 - Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3 fusion. It is a slow-growing lesion associated with a high incidence of pulmonary and brain metastases indicating poor survival. We demonstrated that the ASPS metastases include also stromal myofibroblasts. These cells proliferate, express smooth-muscle genes, and synthesize extracellular matrix proteins, all of which are characteristics of activated myofibroblasts. The tumor cells also exhibited stromal components such as transforming growth factor beta (TGFβ)-dependent, hypoxia-regulated cytoglobin (stellate cell activation association protein, cytg/ STAP) and prolyl 4-hydroxylase, a collagen cross-linking enzyme. The pulmonary ASPS myofibroblasts synthesize serum response factor (SRF), a repressor of Smad3-mediated TGFβ signaling essential for myofibroblast differentiation and Smad3. The phosphorylated active Smad3 was found mostly in the tumor cells. The brain tumor cells express cytg/STAP, but in contrast to the lung metastases, they also express SRF, Smad3, and phospho-Smad3. Halofuginone, an inhibitor of myofibroblasts' activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. This inhibition was associated with the inhibition of TGF(3/SRF signaling, with the inhibition of myofibroblasts' activation, and with the complete loss in TFE3 synthesis by the tumor cells. These results suggest that the myofibroblasts may serve as a novel target for treatment of ASPS metastases.

AB - Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3 fusion. It is a slow-growing lesion associated with a high incidence of pulmonary and brain metastases indicating poor survival. We demonstrated that the ASPS metastases include also stromal myofibroblasts. These cells proliferate, express smooth-muscle genes, and synthesize extracellular matrix proteins, all of which are characteristics of activated myofibroblasts. The tumor cells also exhibited stromal components such as transforming growth factor beta (TGFβ)-dependent, hypoxia-regulated cytoglobin (stellate cell activation association protein, cytg/ STAP) and prolyl 4-hydroxylase, a collagen cross-linking enzyme. The pulmonary ASPS myofibroblasts synthesize serum response factor (SRF), a repressor of Smad3-mediated TGFβ signaling essential for myofibroblast differentiation and Smad3. The phosphorylated active Smad3 was found mostly in the tumor cells. The brain tumor cells express cytg/STAP, but in contrast to the lung metastases, they also express SRF, Smad3, and phospho-Smad3. Halofuginone, an inhibitor of myofibroblasts' activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. This inhibition was associated with the inhibition of TGF(3/SRF signaling, with the inhibition of myofibroblasts' activation, and with the complete loss in TFE3 synthesis by the tumor cells. These results suggest that the myofibroblasts may serve as a novel target for treatment of ASPS metastases.

UR - http://www.scopus.com/inward/record.url?scp=50949115026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949115026&partnerID=8YFLogxK

U2 - 10.1593/neo.08456

DO - 10.1593/neo.08456

M3 - Article

C2 - 18714394

AN - SCOPUS:50949115026

VL - 10

SP - 940

EP - 948

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 9

ER -